The global expanded hemodialysis therapy market is estimated to garner a large revenue by recording a CAGR of ~6% over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing prevalence of hypertension and diabetes, growing number of patients of end-stage renal disease (ESRD), and rising technological advancements associated with developing innovative therapies. According to the International Diabetes Foundation, in 2020, about 463 million adults aged between 20 to 79 years were living with diabetes, the population of which is calculated to rise up to 700 million by 2045. Along with these, escalating number of dialysis centers and rise in preference for expanded hemodialysis therapy among patients are also projected to drive market growth in the near future. Furthermore, growing shortage of organ donors and emerging markets in developing regions are expected to offer ample growth opportunities to the market in the upcoming years. CLICK TO DOWNLOAD SAMPLE REPORT
The market is segmented by modality into short daily, conventional long-term, and nocturnal, out of which, the conventional long-term segment is anticipated to hold the largest share in the global expanded hemodialysis therapy market on account of the high acceptance of expanded hemodialysis therapy among patients suffering from chronic kidney disease and ESRD. In addition, growing focus of prominent manufacturers on developing advanced dialysis equipment is also predicted to boost the growth of the market segment by the end of 2030. Moreover, on the basis of end user, the segment for independent dialysis is projected to occupy the largest share over the forecast period owing to the growing number of dialysis centers across the globe and rising availability of skilled healthcare professionals in dialysis centers.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global expanded hemodialysis therapy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. The market in the Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of rising per capita income, increasing government initiatives supporting the usage of advanced medical therapies and significant improvements in healthcare infrastructure. Apart from these, growing geriatric population is also assessed to drive market growth in the region. Additionally, the market in North America is projected to grab the largest market share during the forecast period owing to the high healthcare spending, increasing occurrence of chronic kidney diseases and strong presence of market players in the region. As per the United States Centers for Disease Control and Prevention, more than 1 in 7, that is 37 million people or 15 percent of the country’s total population is estimated to have chronic kidney disease.
The global expanded hemodialysis therapy market is further classified on the basis of region as follows:
Our in-depth analysis of the global expanded hemodialysis therapy market includes the following segments:
FREQUENTLY ASKED QUESTIONS
The major growth drivers for the market are growing prevalence of diabetes and hypertension and increasing technological advancements to develop innovative therapies.
The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2022 – 2030.
Complications and risks associated with dialysis is estimated to hamper the market growth.
Asia Pacific will provide more business opportunities for market growth owing to the rising per capita income and significant improvements in healthcare infrastructure in the region.
The major players in the market are B. Braun Melsungen AG, Asahi Kasei Corporation, Baxter International, Inc., Fresenius Medical Care AG & Co. KGaA, Nikkiso Co., Ltd., and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by product, modality, end user, and by region.
The independent dialysis segment is anticipated to hold largest market size and is estimated to grow at a notable CAGR over the forecast period and display significant growth opportunities.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization